The drug FTY720 is approved for the treatment of multiple sclerosis. Although highly effective it can have serious side effects. Understanding the molecular mechanisms by which the drug affects its target could lead to the development of a drug with the same therapeutic efficacy but reduced side effects. In this context, researchers have now detailed the molecular mechanism by which FTY270 causes adverse effects in the lungs of mice.